Abstract 1751: BPI-23314: A novel orally bioavailable small molecular BET inhibitor with target protein degradation activity
Jing Guo(Qingdao University), Jiabing Wang(Taizhou Municipal Hospital), Bo Yu(Stanford University), Yan Xu(University of California, Berkeley), Dan Yan(Jacksonville College), Xiaofeng Xu(Hangzhou Normal University), Haibo Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiangyong Liu(Betta Pharmaceuticals (China)), Weiwei Yu(Nanjing Drum Tower Hospital), Lieming Ding(Betta Pharmaceuticals (China)), Hong Lan(Betta Pharmaceuticals (China))
Cited by 0
Related Papers
Cardiac Repair in a Porcine Model of Acute Myocardial Infarction with Human Induced Pluripotent Stem Cell-Derived Cardiovascular Cells
|Cell stem cell|2014|450
Leptin-induced Epithelial-Mesenchymal Transition in Breast Cancer Cells Requires β-Catenin Activation via Akt/GSK3- and MTA1/Wnt1 Protein-dependent Pathways
|Journal of Biological Chemistry|2012|194
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
|The Lancet Respiratory Medicine|2019|139